FDA ESG NextGen: What It Means for Medical Device and SaMD Companies

By Shannon Campbell, PhD, Principal Consultant, Frank Healthcare Advisors

The U.S. Food and Drug Administration has taken a significant step toward modernizing regulatory infrastructure with the rollout of the Electronic Submissions Gateway Next Generation (ESG NextGen). While at first glance this may appear to be a technical upgrade, it represents a broader shift toward digitally enabled, scalable, and automation-ready regulatory interactions; a shift that is particularly relevant for companies developing software as a medical device (SaMD) and AI/ML-enabled technologies.

For small and mid-sized innovators, understanding how ESG NextGen fits into the broader FDA submission ecosystem, and how to operationalize it efficiently, will be increasingly important.

Key Takeaways:

• ESG NextGen is the FDA’s modern, cloud-based submission gateway

• It enables higher capacity, automation, and improved security

• It complements, rather than replaces, eSTAR and the CDRH Portal

• It is particularly relevant for data-intensive and AI-enabled devices

• Companies should begin planning for digitally scalable regulatory workflows

What is ESG NextGen?

ESG NextGen is the FDA’s modernized, cloud-based platform for receiving and routing electronic regulatory submissions. It replaces legacy systems (such as WebTrader) with a more scalable, secure, and flexible infrastructure.

At its core, ESG NextGen functions as a secure transmission gateway by:

• Receiving electronic files from sponsors

• Performing validation and acknowledgment

• Routing submissions to the appropriate FDA Center (e.g., CDRH, CDER, CBER)

ESG NextGen serves as a “unified entry point for all submission types,” with significantly enhanced capacity and improved performance for high-volume or data-intensive workflows.

Key Features and Capabilities

1. Unified Submission Portal (USP)

A web-based interface replaces the legacy WebTrader system, allowing users to upload submissions, track submission status, and receive acknowledgments across FDA Centers. This improves usability, particularly for organizations without dedicated regulatory IT infrastructure.

2. Multiple Submission Pathways, Including API-Enabled Submissions

One of the most important upgrades is API integration, which enables:

• Automated submission workflows

• Integration with internal regulatory systems

• Real-time status tracking

Companies can also submit via Web portal (USP) or AS2 connections.

Each pathway includes automated validation and acknowledgment workflows, reducing submission uncertainty and delays. For AI/ML companies operating continuous development cycles, this opens the door to more scalable regulatory operations.

3. High-Capacity Data Handling

ESG NextGen supports submissions up to 1 terabyte, a major increase over legacy constraints. This is particularly relevant for:

• Imaging-heavy SaMD (e.g., radiology, cardiology platforms)

• AI/ML training or validation datasets

• Real-world evidence (RWE) packages

4. Enhanced Security and Identity Management

The platform introduces a unified Identity and Access Management (IAM) system, simplifying user credential management, organizational access control, and security compliance

ESG NextGen in Context: Not a Replacement for eSTAR or CDRH Portal

A critical point for medical device companies is that ESG NextGen does not replace existing CDRH-specific tools, but rather complements them.

Tool	Role
eSTAR	Content creation and validation (mandatory for 510(k) and De Novo)
CDRH Portal	Preferred upload pathway for most device submissions
ESG NextGen	Agency-wide transmission gateway

For most SaMD companies:

• eSTAR + CDRH Portal will remain the primary pathway for premarket submissions

• ESG NextGen becomes relevant for:

  • Large or complex submissions

  • Cross-center interactions (e.g., combination products, CBER involvement)

  • Automated or high-frequency submission environments

Practical Considerations for Companies

For small and mid-sized device developers, the key question is not whether to use ESG NextGen, but when and how to incorporate it into your regulatory strategy.

Recommended approach:

• Continue using eSTAR + CDRH Portal for standard device submissions

• Evaluate ESG NextGen if you:

  • Manage large datasets or imaging-heavy submissions

  • Plan to scale submission frequency

  • Want to automate regulatory workflows

  • Interact across multiple FDA Centers

    
    

FHA Perspective

At Frank Healthcare Advisors, we view ESG NextGen as more than a technical upgrade, it is part of a broader FDA transition toward digitally integrated regulatory ecosystems.

For innovators in SaMD and AI/ML:

• Regulatory strategy must now consider not just what you submit, but how you submit it

• Early alignment of data structure, validation outputs, and submission pathways can reduce downstream friction

• Scalable regulatory infrastructure is becoming a competitive advantage, not just an operational detail